Drs Kathy Miller and Francisco J. Esteva discuss testing and therapeutic options for the new classification of HER2-ultra-low breast cancer.

*仅供医学专业人士阅读参考近30%的早期乳腺癌患者在术前活检与新辅助治疗后残留病变之间的HER2表达会发生变化，并且仅HER2阳性向阴性的转变具有预后意义。乳腺癌是导致女性癌症相关死亡的主要原因之一。在浸润性乳腺癌病例中，人表皮生长因子受体2（HER ...

New DESTINY-Breast06 analysis showed trastuzumab deruxtecan doubled PFS versus chemotherapy in patients with rapid ...

Olaparib Demonstrates Survival Benefit in Early Breast Cancer: Data from the phase 3 OlympiA trial (NCT02032823) showed that ...

[1]Tarantino P, Hamilton E, Tolaney SM, et al. HER2-Low Breast Cancer: Pathological and Clinical Landscape. J Clin Oncol. 2020;38(17):1951-1962. [2]Marty M, Cognetti F, Maraninchi D, et al ...

Researchers presented data from trials of HER2-targeted therapies from Jiangsu Hengrui Medicine, Jazz Pharma, Roche, and RemeGen.

The most-read breast cancer articles include topics on hereditary breast cancer, hormone therapy benefits, BRCA mutations, as ...

Imlunestrant, an oral SERD, significantly prolonged progression-free survival in patients with advanced ER+, HER2- breast ...

WEILL CORNELL MEDICINE PRESENTS HER2 PARSORTIX WORKFLOW AT SAN ANTONIO BREAST CANCER SYMPOSIUM. Independent findings support ANGLE's HER2 assay development programme. Potential fo ...